Industry Leading Hybridoma Technique For Accelerated Antibody Discovery

The hybridoma technique remains the gold standard for monoclonal antibody (mAb) production, responsible for generating 90% of FDA-approved antibodies. Monoclonal antibodies have diverse applications, including diagnostics, therapeutics, and analytical tools. With over 80 mAbs approved globally and more than 700 antibody-based molecules in various stages of clinical trials, demand for efficient and reliable antibody production methods continues to grow.

Hybridoma technology enables the efficient isolation of mAbs while ensuring the native pairing of variable and constant region gene combinations. This method naturally preserves the pairing of heavy and light chain genes and facilitates class switch recombination (CSR), allowing for the production of mature antibodies with naturally class-switched constant regions. Unlike other mAb isolation methods, which lack this spontaneous CSR flexibility, hybridoma technology remains a uniquely powerful strategy for generating fully functional in vivo antibodies.

At Aragen Life Sciences, we have successfully developed a high-performing hybridoma cell production platform to support the efficient generation of a wide range of monoclonal antibodies. Our comprehensive end-to-end services cover every stage of antibody discovery and development, from antigen design to high-throughput screening for binders against native epitopes, including complex screening strategies. Additionally, our capabilities extend to purification analytics, recombinant protein generation, and cell line development, ensuring seamless and scalable antibody production to meet research and therapeutic needs.